Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
dermatitis save search
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
CRVS | $1.43 5.15% 4.9% 140K
|
Health Technology
|
| O: 2.45%
H: 0.0%
C: -9.58%
dermatitis pharmaceuticals for trial
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
Lynk Pharmaceuticals Announces First Atopic Dermatitis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
lnk0100 first dermatitis pharmaceuticals study
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
ASLN | $0.539 9.78% 8.91% 300K
|
Health Technology
|
| O: 0.16%
H: 203.51%
C: 160.38%
dermatitis update pharmaceuticals potential study
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
Published: 2024-03-11 (Crawled : 06:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
dermatitis response potential results
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Published: 2024-03-10 (Crawled : 20:20) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.3%
H: 0.61%
C: -2.37%
dermatitis skin study
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Published: 2024-03-10 (Crawled : 20:20) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 0.18%
H: 3.39%
C: -10.12%
children dermatitis meeting trial
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
Published: 2024-03-09 (Crawled : 00:20) - arcutis.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
| Email alert
Add to watchlist
genomic dermatitis research key skin response
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
Published: 2024-03-05 (Crawled : 11:00) - globenewswire.com
APGE | $48.4 -6.02% -6.4% 390K
|
|
| O: 43.53%
H: 9.18%
C: -1.02%
apg777 antibody dermatitis positive treatment trial results
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
APGE | $48.4 -6.02% -6.4% 390K
|
|
| O: 43.53%
H: 9.18%
C: -1.02%
apg777 conference report antibody dermatitis treatment trial results
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Published: 2024-03-04 (Crawled : 14:00) - arcutis.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 2.29%
H: 2.57%
C: -9.05%
dermatitis meeting
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 3.4%
H: 10.95%
C: 10.58%
dermatitis zoryve trial results
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: 5.85%
H: 7.56%
C: 2.91%
zoryve dermatitis treatment
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
urticaria dermatitis trials
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.03%
H: 0.05%
C: 0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.34%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.21%
H: 0.67%
C: 0.66%
dupixent label dermatitis
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
Published: 2024-01-14 (Crawled : 12:20) - arcutis.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
| Email alert
Add to watchlist
dermatitis program
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
Published: 2024-01-14 (Crawled : 12:20) - arcutis.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
| Email alert
Add to watchlist
zoryve dermatitis response
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
ACRS | $1.235 0.41% 0.4% 650K
|
Health Technology
|
| O: -16.41%
H: 6.54%
C: -6.07%
ati-1777 dermatitis trial therapeutics results
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
ALDX | News | $3.99 0.5% 0.5% 430K
|
Health Technology
|
| O: 1.32%
H: 3.27%
C: -3.27%
adx-629 conference dermatitis trial therapeutics results
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
CARA | $0.69 -5.73% -6.07% 360K
|
Health Technology
|
| O: -4.88%
H: 0.0%
C: -46.23%
pruritus dermatitis therapeutics study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.